Fenlai Tan

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Fenlai Tan, Xiaoyan Shen, Dechang Wang et al. · Lung Cancer · 2011 · 133 citations

Medicine, Preclinical Studies, Receptor Tyrosine Kinase +6

Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis

Gilles Delmas, S. Park, Z. W. Chen et al. · Antimicrobial Agents and Chemotherapy · 2002 · 112 citations · Full text

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Qiong Zhao, Jianzhong Shentu, Nong Xu et al. · Lung Cancer · 2010 · 97 citations

Advanced Nsclc, Oncology, Medicine +7

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Jing Huang, Qingxia Fan, Ping Lu et al. · Journal of Thoracic Oncology · 2016 · 83 citations · Full text

Esophageal Cancer, Medicine, Multicenter Phase 2 +8